Lexatumumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.

**Synonyms:** - Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2 - HGS-ETR2 - HGS-ETR2 - HGS-ETR2 - HGS1018 - LEXATUMUMAB - Monoclonal Antibody HGS-ETR2 - anti-TRAIL R2 mAb HGS-ETR2 - lexatumumab